logo
Folia Health and Inspire are Partnering to Bring Personalized Home Health Observations to the Forefront of Patient Focused Drug Development Research

Folia Health and Inspire are Partnering to Bring Personalized Home Health Observations to the Forefront of Patient Focused Drug Development Research

Yahoo30-04-2025

BOSTON, April 30, 2025 (GLOBE NEWSWIRE) -- Folia Health, the pioneer of patient-driven Home Reported Outcomes (HRO), has partnered with Inspire, the world's leading online health community and real-world data platform, to uniquely empower patients and caregivers with the opportunity to contribute a highly personalized form of structured at-home health observations data to accelerate patient-focused drug development research. In this collaboration, Folia and Inspire will focus on building longitudinal Real-World Evidence (RWE) Communities in some of the most complex and heterogeneous conditions to unlock insights that have been previously unattainable and unmeasurable in other data sources.
Folia's HRO technology platform and user experience (UX) have been designed in collaboration with patients, caregivers, and clinicians to generate longitudinal insights that are dynamic to each individual. By allowing participants to self-select and define what's most meaningful to share about their lived disease experiences, we can now uncover aspects of diseases that have been the most difficult for researchers to understand and measure when developing novel therapies.
'We are thrilled to partner with Inspire to engage their member communities with our innovative, app-based solution that has been designed to bridge the gap between clinical care decision making and real-world evidence research. These RWE Communities within Inspire's member populations will provide a truly unique combination of real-world data that is required to answer the toughest questions in drug development and reimbursement today.' Nell Meosky Luo - CEO of Folia Health.
As the world's largest online health community, Inspire is the go-to platform for patient and caregiver data, research and engagement. Inspire offers unique access to focused patient populations to support initiatives at every phase of development – from preclinical to post-approval marketing. Inspire is a trusted partner to over 100 patient advocacy organizations, and continues to identify opportunities that put patients and caregivers at the forefront of the most important questions in healthcare.
'At Inspire, we believe that empowering patients and caregivers to contribute their lived experiences is essential to driving meaningful research. By integrating Folia's innovative home-reported outcomes with our engaged health communities, we're unlocking new possibilities for real-world evidence generation that reflects the true patient journey—ultimately accelerating patient-focused drug development.' Brett Kleger - CEO of Inspire.
Folia | Inspire - Revolutionizing Patient-Centered Real-World Evidence ResearchThis partnership enables the first large-scale digital approach to collecting the real-world lived experiences of patients outside of the clinic setting using Folia's HROs, and will directly measure patient-defined burden and the impact of various treatments on quality of life. These insights will be integrated with Inspire's member linked administrative claims data, EMR records, and AI enabled social media listening insights for the most robust patient-level insights available for patient-focused drug development research available today. The fully remote research model eliminates the need for clinic visits or research sites, while equipping patients with powerful insights to share with their care teams to ultimately receive more precise care. Unlike nearly every current research method today, HROs allow patients and caregivers to actively engage with their own study observations, gaining deeper insights into their personal symptom burden, treatment effects, and flare-up events that are commonly associated with complex diseases, while also seamlessly contributing their data for research.
About Folia Health:
Folia Health's home-reported outcomes (HROs) method and technology is pioneering the next generation of patient health data by transforming lived health experiences that occur at-home into valuable structured data insights to support research and personalized care. Through an innovative platform backed by expert analysis, we help life science partners develop effective therapies with demonstrated, real-world value for complex, chronic conditions. Folia's wealth of longitudinal data and proprietary analytics play a vital role in establishing a home-centered, data-driven healthcare ecosystem. Folia's platform is private, secure, and allows users to decide when and how their data is shared, while generating insightful trends, visualizations, and reports in the platform that allow them to receive more precise, data driven care. To explore the transformative potential of patient and caregiver knowledge, visit www.foliahealth.com.
About Inspire:
Founded in 2005, Inspire is the leading health community, connecting over 10 million patients and caregivers across 3,000 disease areas. Through its robust patient-centric platform, Inspire supports initiatives across the clinical development lifecycle—from preclinical research to post-market access—enabling life sciences organizations to capture real-world insights and accelerate medical advancements. For more information, visit www.inspireresearch.com
Folia Health Contact:Connie Zhangconnie@foliahealth.com
Inspire Contact:Jillian Tyghjillian.tygh@inspire.comSign in to access your portfolio

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Inspire Medical Systems, Inc. to Participate in the Wells Fargo 2025 MedTech Innovation Spotlight
Inspire Medical Systems, Inc. to Participate in the Wells Fargo 2025 MedTech Innovation Spotlight

Yahoo

time22 minutes ago

  • Yahoo

Inspire Medical Systems, Inc. to Participate in the Wells Fargo 2025 MedTech Innovation Spotlight

MINNEAPOLIS, May 30, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will participate in the Wells Fargo 2025 MedTech Innovation Spotlight on Friday, June 13, 2025. Inspire is scheduled to present at 12:00 p.m. Eastern Time. The presentation will be accessible via a live webcast here. A webcast replay of the presentation will be available for two weeks following the presentation in the Event Archive section of Inspire's Investor website at About Inspire Medical SystemsInspire is a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. Inspire's proprietary Inspire therapy is the first and only FDA, EU MDR, and PDMA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. For additional information about Inspire, please visit Investor and Media ContactEzgi YagciVice President, Investor Relationsezgiyagci@ in to access your portfolio

New sleep apnea therapy offered at CarolinaEast Health System
New sleep apnea therapy offered at CarolinaEast Health System

Yahoo

time2 days ago

  • Yahoo

New sleep apnea therapy offered at CarolinaEast Health System

NEW BERN, N.C. (WNCT) — A medical team with the CarolinaEast Health System are offering a new solution for those who struggle with a CPAP machine. Medical personnel with the Ear, Nose and Throat section of CarolinaEast are now making Inspire therapy available to the public. They have just completed their 50th Inspire implant. Inspire therapy helps those who have obstructive sleep apnea and struggle to use a CPAP. It offers a long-term and mask-free solution by syncing with the patient's natural breathing pattern and keeps their airway open. 'We are excited to stay on the cutting edge of technology for our patients in coastal NC,' stated Dr. McNabb, Otolaryngologist. 'The new Inspire therapy is one more tool to help those who suffer from sleep apnea get the rest they need.' The procedure involves two incisions, one in the chest and one under the chin where the nerve that controls the airway muscles is located. The Inspire implant and breathing sensors are placed in the chest incision. A handheld remote is given to the patient for them to turn the implant on when they're ready to sleep. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

FDA Approves Liquidia Corporation (LQDA)'s YUTREPIA Amid Patent Dispute
FDA Approves Liquidia Corporation (LQDA)'s YUTREPIA Amid Patent Dispute

Yahoo

time6 days ago

  • Yahoo

FDA Approves Liquidia Corporation (LQDA)'s YUTREPIA Amid Patent Dispute

Liquidia Corporation (NASDAQ:LQDA) announced today that the U.S. Food and Drug Administration (FDA) has approved YUTREPIA (treprostinil) inhalation powder for adults with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). A healthcare professional working on a computer terminal with a patient in the background. YUTREPIA, enabled by Liquidia Corporation (NASDAQ:LQDA)'s proprietary PRINT technology, is the first and only prostacyclin dry-powder formulation designed for deep-lung delivery using a low-effort, portable inhalation device. The approval is based on results from the Phase 3 INSPIRE trial, which showed YUTREPIA to be safe and well-tolerated, offering a new treatment option for over 105,000 U.S. patients suffering from PAH and PH-ILD. Liquidia Corporation (NASDAQ:LQDA)'s commercial team is preparing to launch YUTREPIA, aiming to improve exercise ability and quality of life for patients. However, United Therapeutics Corporation has filed a patent infringement lawsuit and is seeking a court order to block YUTREPIA's commercial launch, with a decision on the injunction still pending. While we acknowledge the potential of LQDA to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than LQDA and that has 100x upside potential, check out our report about this READ NEXT: and Disclosure: None. Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store